Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.
Oncologist · 2026-Jun-06 · PMID 42179186
time to first ≥50% reduction in MFSAF TSS
Figure 3. Change in MFSAF TSSs from baseline and likelihood of achieving a ≥50% reduction from baseline in MFSAF TSS in patients with myelofibrosis. (A) Percentage change in MFSAF TSS from baseline to week 24 (individual patient data; n = 117). Dotted line represents a 50% decrease in MFSAF TSS from baseline. (B) Median percentage change in MFSAF TSS from baseline. (C) Kaplan-Meier estimates of time to first ≥50% reduction in MFSAF TSS from baseline. Hashtags indicate patients with >100% percent change in MFSAF TSS from baseline. Tick marks indicate censored data. MFSAF, Myelofibrosis Symptom Assessment Form; TSS, total symptom score.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T17:51:55+00:00 |